SERPINE1
|
0.080 |
Biomarker
|
group |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) has already been associated with atherosclerosis; myocardial infarction; and cardiovascular disease risk factors such as obesity, insulin resistance, and dyslipidemia.
|
20127289 |
2010 |
SERPINE1
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Several association studies have shown that -844 G/A and HindIII C/G PAI-1 polymorphisms are related with increase of PAI-1 levels, obesity, insulin resistance, glucose intolerance, hypertension and dyslipidemia, which are components of metabolic syndrome.
|
22459021 |
2012 |
SERPINE1
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Furthermore, increased plasma PAI-1 levels are associated with dyslipidemia, hyperinsulinemia and hypertension.
|
10867719 |
2000 |
SERPINE1
|
0.080 |
Biomarker
|
group |
BEFREE |
These results suggest that elevated PAI-1 and fibrinogen in Asians of both genders may contribute to the increased vascular risk experienced in this population; however, the role of dyslipidaemia and Factor VII are not clear in these processes.
|
11395044 |
2001 |
SERPINE1
|
0.080 |
Biomarker
|
group |
BEFREE |
Especially PAI-1 and TNFalpha accompany insulin resistance and dyslipidemia.
|
18278185 |
2008 |
SERPINE1
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Especially a defective insulin response in the liver contributes to the development of hyperglycemia, dyslipidemia and peripheral insulin resistance and may contribute to hepatic over-expression of PAI-1 in diabetes type 2.
|
19132222 |
2008 |
SERPINE1
|
0.080 |
AlteredExpression
|
group |
LHGDN |
Especially PAI-1 and TNFalpha accompany insulin resistance and dyslipidemia.
|
18278185 |
2008 |
SERPINE1
|
0.080 |
Biomarker
|
group |
BEFREE |
Van also significantly inhibited hyperglycaemia-induced blood levels of coagulation (vWF) and thrombosis (PAI-1 and fibrinogen) biomarkers.<b>Conclusions:</b> Vanadyl sulphate effectively suppresses hyperglycaemia-induced endothelial injury, coagulation and thrombosis, which is associated with the inhibition of inflammation and dyslipidemia.
|
31774317 |
2019 |
SERPINE1
|
0.080 |
Biomarker
|
group |
BEFREE |
PAI-1 appears to be tightly related to both histologic severity of NAFLD as well as systemic features of the disease including insulin resistance and dyslipidemia.
|
27764892 |
2018 |